TP53 loss-of-function causes vulnerability to autophagy inhibition in aggressive prostate cancer.
Yong ZhangXian-Li SongBin YuLian-Chee FoongYu ShuChun Wai MaiJing HuBaijun DongWei XueChee Wai ChuaPublished in: International journal of urology : official journal of the Japanese Urological Association (2022)
Our results support the potential use of autophagy inhibitors in prostate cancers that contain TP53 loss-of-function mutations.